Canlyniadau Chwilio - Vital, Edward

Lots of autoantibodies equal lupus? gan Aringer, Martin, Vital, Edward

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Abatacept in the treatment of rheumatoid arthritis gan Vital, Edward M, Emery, Paul

Cael y testun llawn Cael y testun llawn

Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization gan Md Yusof, Md Yuzaiful, Vital, Edward M

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Abatacept in the treatment of rheumatoid arthritis gan Buch, Maya H, Vital, Edward M, Emery, Paul

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE gan Dutton, Katherine, Savic, Sinisa, Owen, Roger, Vital, Edward

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab gan Daniel, Alexandra, Bagnato, Gianluca, Vital, Edward, Del Galdo, Francesco

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? gan Romão, Vasco C., Vital, Edward M., Fonseca, João Eurico, Buch, Maya H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases—A Focus on Psoriasis and Lupus erythematosus gan Berekméri, Anna, Tiganescu, Ana, Alase, Adewonuola A., Vital, Edward, Stacey, Martin, Wittmann, Miriam

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab gan Hassan, Sabih Ul, Md Yusof, Md Yuzaiful, Emery, Paul, Dass, Shouvik, Vital, Edward M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus gan Dörner, Thomas, Vital, Edward M., Ohrndorf, Sarah, Alten, Rieke, Bello, Natalia, Haladyj, Ewa, Burmester, Gerd

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus gan Mahmoud, Khaled, Zayat, Ahmed S, Yusof, Yuzaiful, Hensor, Elizabeth, Conaghan, Philip G, Emery, Paul, Vital, Edward M

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review gan Zayat, Ahmed S., Md Yusof, Md Yuzaiful, Wakefield, Richard J., Conaghan, Philip G., Emery, Paul, Vital, Edward M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation gan Psarras, Antonios, Antanaviciute, Agne, Alase, Adewonuola, Carr, Ian, Wittmann, Miriam, Emery, Paul, Tsokos, George C., Vital, Edward M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A glimpse into the future of systemic lupus erythematosus gan Aringer, Martin, Alarcón-Riquelme, Marta E., Clowse, Megan, Pons-Estel, Guillermo J., Vital, Edward M., Dall’Era, Maria

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre gan Md Yusof, Md Yuzaiful, Kabia, Angela, Darby, Michael, Lettieri, Giovanni, Beirne, Paul, Vital, Edward M., Dass, Shouvik, Emery, Paul

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic gan Marzo-Ortega, Helena, Tan, Ai Lyn, Bissell, Lesley-Anne, Morgan, Ann W, Vandevelde, Claire, Vital, Edward M, Dass, Shouvik

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus gan Md Yusof, Md Yuzaiful, Shaw, Daniel, El-Sherbiny, Yasser M, Dunn, Emma, Rawstron, Andy C, Emery, Paul, Vital, Edward M

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis gan Arnold, Jack, Vital, Edward M., Dass, Shouvik, Aslam, Aamir, Rawstron, Andy C., Savic, Sinisa, Emery, Paul, Md Yusof, Md Yuzaiful

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity gan Psarras, Antonios, Alase, Adewonuola, Antanaviciute, Agne, Carr, Ian M., Md Yusof, Md Yuzaiful, Wittmann, Miriam, Emery, Paul, Tsokos, George C., Vital, Edward M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

De novo lupus nephritis during treatment with belimumab gan Parodis, Ioannis, Vital, Edward M, Hassan, Sabih-Ul, Jönsen, Andreas, Bengtsson, Anders A, Eriksson, Per, Leonard, Dag, Gunnarsson, Iva, Rönnblom, Lars, Sjöwall, Christopher

Cael y testun llawn Cael y testun llawn Cael y testun llawn